keyword
MENU ▼
Read by QxMD icon Read
search

mdr tb

keyword
https://www.readbyqxmd.com/read/28339465/comparative-accuracy-of-the-reba-mtb-mdr-and-hain-mtbdrplus-line-probe-assays-for-the-detection-of-multidrug-resistant-tuberculosis-a-multicenter-non-inferiority-study
#1
Joshua Havumaki, Doris Hillemann, Nazir Ismail, Shaheed Vally Omar, Sophia B Georghiou, Samuel G Schumacher, Catharina Boehme, Claudia M Denkinger
INTRODUCTION: Despite recent diagnostic advances, the majority of multidrug-resistant tuberculosis (MDR-TB) cases remain undiagnosed. Line probes assays (LiPAs) hold great promise to curb the spread of MDR-TB as they can rapidly detect MDR-TB even when laboratory infrastructure is limited, yet few of these assays are currently widely available or supported by World Health Organization (WHO) policy. METHODS: The aim of this prospective, blinded, non-inferiority study was to compare the performance of YD Diagnostics REBA MTB MDR LiPA (YD) to the WHO-endorsed Hain MTBDRplus V1 LiPA (Hain V1) for the detection of rifampicin and isoniazid resistance...
2017: PloS One
https://www.readbyqxmd.com/read/28338827/strategies-for-halting-the-rise-of-multidrug-resistant-tb-epidemics-assessing-the-effect-of-early-case-detection-and-isolation
#2
Aquino L Espindola, Marie Varughese, Marek Laskowski, Affan Shoukat, Jane M Heffernan, Seyed M Moghadas
Background: The increasing rates of multidrug resistant TB (MDR-TB) have posed the question of whether control programs under enhanced directly observed treatment, short-course (DOTS-Plus) are sufficient or implemented optimally. Despite enhanced efforts on early case detection and improved treatment regimens, direct transmission of MDR-TB remains a major hurdle for global TB control. Methods: We developed an agent-based simulation model of TB dynamics to evaluate the effect of transmission reduction measures on the incidence of MDR-TB...
March 7, 2017: International Health
https://www.readbyqxmd.com/read/28336312/old-antibiotics-for-emerging-multidrug-resistant-extensively-drug-resistant-tuberculosis-mdr-xdr-tb
#3
Philippe Brouqui, Fanny Quenard, Michel Drancourt
Recently, multidrug-resistant tuberculosis (MDR-TB) has become a therapeutic challenge. In addition to drug resistance, drug adverse events, intravenous delivery, cost and availability of some antibiotics in low-income countries have led to a look back to old drugs, especially those efficient against closely related organisms such as Mycobacterium leprae. Here we review the available drugs that respect the conditions above and could be upgraded to first-line therapy for treating MDR-TB and extensively drug-resistant tuberculosis (XDR-TB)...
March 21, 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28335544/combination-effect-of-antituberculosis-drugs-and-ethanolic-extract-of-selected-medicinal-plants-against-multi-drug-resistant-mycobacterium-tuberculosis-isolates
#4
Prabasiwi Nur Fauziyah, Elin Yulinah Sukandar, Dhyan Kusuma Ayuningtyas
Adverse drug reaction and resistance to antituberculosis drugs remain the causes of tuberculosis therapeutic failure. This research aimed to find the combination effect of standard antituberculosis drugs with Hibiscus sabdariffa L., Kaempferia galanga L., and Piper crocatum N.E. Br against multi-drug resistant (MDR) Mycobacterium tuberculosis isolates. Two MDR strains (i.e., isoniazid/ethambutol resistant and rifampicin/streptomycin resistant) of M. tuberculosis were inoculated in Löwenstein-Jensen medium containing a combination of standard antituberculosis drugs and ethanolic extracts of H...
March 20, 2017: Scientia Pharmaceutica
https://www.readbyqxmd.com/read/28334761/tackling-the-mdr-tb-epidemic-in-ukraine-every-little-helps-%C3%A2-and-much-more-needed
#5
Matthew Burman, Vladyslav Nikolayevskyy, Irina Kontsevaya, Barbara Molina-Moya, Olena Rzhepishevska, Lorenzo Guglielmetti
No abstract text is available yet for this article.
February 27, 2017: Journal of Public Health
https://www.readbyqxmd.com/read/28334036/multidrug-resistant-tuberculosis-in-prisons-located-in-former-soviet-countries-a-systematic-review
#6
Maxwell Droznin, Allen Johnson, Asal Mohamadi Johnson
BACKGROUND: A systematic literature review was performed to investigate the occurrence of multidrug-resistant tuberculosis (MDR TB) in prisons located in countries formerly part of the Soviet Union. METHODS: A systematic search of published studies reporting MDR TB occurrence in prisons located in former Soviet countries was conducted by probing PubMed and Cumulative Index Nursing and Allied Health Literature for articles that met predetermined inclusion criteria...
2017: PloS One
https://www.readbyqxmd.com/read/28333192/susceptibilities-of-mdr-mycobacterium-tuberculosis-isolates-to-unconventional-drugs-compared-with-their-reported-pharmacokinetic-pharmacodynamic-parameters
#7
Joseph S Cavanaugh, Ruwen Jou, Mei-Hua Wu, Tracy Dalton, Ekaterina Kurbatova, Julia Ershova, J Peter Cegielski
Background: The second-line drugs recommended to treat drug-resistant TB are toxic, expensive and difficult to procure. Given increasing resistance, the need for additional anti-TB drugs has become more urgent. But new drugs take time to develop and are expensive. Some commercially available drugs have reported anti-mycobacterial activity but are not routinely used because supporting laboratory and clinical evidence is sparse. Methods: We analysed 217 MDR M. tuberculosis isolates including 153 initial isolates from unique patients and 64 isolates from follow-up specimens during the course of treatment...
February 20, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28331350/risk-factors-for-multidrug-resistant-tuberculosis-among-tuberculosis-patients-a-case-control-study
#8
Abdulhalik Workicho, Wondwosen Kassahun, Fessahaye Alemseged
BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) did not receive major attention until recently in sub-Saharan Africa where the tuberculosis incidence and risk factors are highest. Factors leading to development of drug resistance need to be understood to develop appropriate control strategies for national programs. The objective of this study was to identify the risk factors for MDR-TB among tuberculosis patients. METHODS: A case-control study was conducted to assess sociodemographic, behavioral and clinical risk factors using a structured questionnaire and clinical record reviewing...
2017: Infection and Drug Resistance
https://www.readbyqxmd.com/read/28331348/molecular-detection-of-multidrug-resistant-tuberculosis-among-smear-positive-pulmonary-tuberculosis-patients-in-jigjiga-town-ethiopia
#9
Mussie Brhane, Ameha Kebede, Yohannes Petros
BACKGROUND: Molecular methods that target drug resistance mutations are suitable approaches for rapid drug susceptibility testing to detect multidrug-resistant tuberculosis (MDR-TB). The aim of the study was to determine MDR-TB cases and to analyze the frequency of gene mutations associated with rifampicin (RIF) and/or isoniazid (INH) resistance of Mycobacterium tuberculosis among smear-positive pulmonary tuberculosis patients. METHODS: Institution-based cross-sectional study design was employed...
2017: Infection and Drug Resistance
https://www.readbyqxmd.com/read/28331044/effectiveness-and-safety-of-clofazimine-in%C3%A2-multidrug-resistant-tuberculosis-a%C3%A2-nationwide-report-from-brazil
#10
Margareth Dalcolmo, Regina Gayoso, Giovanni Sotgiu, Lia D'Ambrosio, Jorge L Rocha, Liamar Borga, Fatima Fandinho, Jose U Braga, Vera M N Galesi, Draurio Barreira, Denise A Sanchez, Fernanda Dockhorn, Rosella Centis, Jose A Caminero, Giovanni B Migliori
Although clofazimine is used to treat multidrug-resistant tuberculosis (MDR-TB), there is scant information on its effectiveness and safety. The aim of this retrospective, observational study was to evaluate these factors as well as the tolerability of clofazimine in populations in Brazil, where it was administered at a daily dose of 100 mg·day(-1) (body weight ≥45 kg) as part of a standardised MDR-TB treatment regimen until 2006 (thereafter pyrazinamide was used).All MDR-TB patients included in the Sistema de Informação de Tratamentos Especiais da Tuberculose (SITETB) individual electronic register were analysed...
March 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28331043/world-health-organization-treatment-guidelines-for-drug-resistant-tuberculosis-2016-update
#11
Dennis Falzon, Holger J Schünemann, Elizabeth Harausz, Licé González-Angulo, Christian Lienhardt, Ernesto Jaramillo, Karin Weyer
Antimicrobial resistance is a major global concern. Tuberculosis (TB) strains resistant to rifampicin and other TB medicines challenge patient survival and public health. The World Health Organization (WHO) has published treatment guidelines for drug-resistant TB since 1997 and last updated them in 2016 based on reviews of aggregated and individual patient data from published and unpublished studies. An international expert panel formulated recommendations following the GRADE approach. The new WHO guidelines recommend a standardised 9-12 months shorter treatment regimen as first choice in patients with multidrug- or rifampicin-resistant TB (MDR/RR-TB) strains not resistant to fluoroquinolones or second-line injectable agents; resistance to these two classes of core second-line medicines is rapidly detectable with molecular diagnostics also approved by WHO in 2016...
March 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28331031/an-updated-systematic-review-and-meta-analysis-for-treatment-of-multidrug-resistant-tuberculosis
#12
Mayara Lisboa Bastos, Zhiyi Lan, Dick Menzies
This systematic review aimed to update the current evidence for multidrug-resistant tuberculosis (MDR-TB) treatment.We searched for studies that reported treatment information and clinical characteristics for at least 25 patients with microbiologically confirmed pulmonary MDR-TB and either end of treatment outcomes, 6-month culture conversion or severe adverse events (SAEs). We assessed the association of these outcomes with patients' characteristics or treatment parameters. We identified 74 studies, including 17 494 participants...
March 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28330890/direct-detection-of-rifampicin-and-isoniazid-resistance-in-sputum-samples-from-tuberculosis-patients-by-high-resolution-melt-curve-analysis
#13
Divya Anthwal, Rakesh Kumar Gupta, Manpreet Bhalla, Shinjini Bhatnagar, Jaya Sivaswami Tyagi, Sagarika Haldar
Drug-resistant tuberculosis (TB) is a major threat for TB control worldwide. Globally, only 40% of the 340,000 notified TB patients estimated to have multidrug resistant-TB (MDR-TB) were detected in 2015. This study was carried out to evaluate the utility of High Resolution Melt curve analysis (HRM) for the rapid and direct detection of MDR-TB in Mycobacterium tuberculosis (M. tb) in sputum samples. A reference plasmid library was first generated of the most frequently observed mutations in the resistance determining regions of rpoB, katG and inhA promoter and used as positive controls in HRM...
March 22, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28330178/emergence-of-mixed-infection-of-beijing-non-beijing-strains-among-multi-drug-resistant-mycobacterium-tuberculosis-in-pakistan
#14
Samar Mustafa, Hasnain Javed, Jawairia Hashmi, Nazia Jamil, Zarfishan Tahir, Abdul Majeed Akhtar
Tuberculosis (TB) remains as one of the deadliest diseases after HIV globally with 95 % of deaths confined to low-and-middle income countries. Pakistan is fifth among the 22 high-burden TB countries with the incidence rate of 230/100,000 persons, however, studies related to prevalent Mycobacterium tuberculosis strains and their spread, drug resistance pattern and evolutionary genetics are inadequate. The present study was undertaken to highlight the circulation of M. tuberculosis strains causing drug resistant TB in our community by targeting the molecular marker IS6110 and then characterization of these strains as Beijing and Non-Beijing genotypes...
June 2016: 3 Biotech
https://www.readbyqxmd.com/read/28329197/systematic-review-meta-analysis-and-cost-effectiveness-of-treatment-of-latent-tuberculosis-infection-to-reduce-progression-to-multidrug-resistant-tuberculosis
#15
Suzanne M Marks, Sundari R Mase, Sapna Bamrah Morris
Background: Evidence-based recommendations for treating persons having presumed latent tuberculosis infection (LTBI) after contact to infectious multidrug-resistant tuberculosis (MDR TB) are lacking because published data consist of small observational studies. TB incidence in persons treated for latent multidrug-resistant-TB infection (MDR LTBI) is unknown. Methods: We conducted a systematic review of studies published (1/1/1994-12/31/2014) to analyze TB incidence, treatment completion and discontinuation, and cost effectiveness...
March 14, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28327117/preliminary-evaluation-of-anti-tuberculosis-potential-of-siderophores-against-drug-resistant-mycobacterium-tuberculosis-by-mycobacteria-growth-indicator-tube-drug-sensitivity-test
#16
Karuna Gokarn, Ramprasad B Pal
BACKGROUND: Alternative treatment strategies have become essential in overcoming the problem of drug-resistant Mycobacterium tuberculosis (Mtb). In this preliminary in vitro study, the anti-tuberculosis (anti-TB) activity of exogenous iron chelators (xenosiderophores) such as Exochelin-MS (Exo-MS) and Deferoxamine-B (DFO-B) was evaluated against ten multi-drug-resistant (MDR) and seven pyrazinamide-resistant (PZA (R) ) Mtb isolates. METHODS: Mycobacteria Growth Indicator Tube-Drug Susceptibility Test was used to assess the anti-TB effect of Exo-MS or DFO-B individually and their combinations with isoniazid (INH), rifampicin (RIF) and pyrazinamide (PZA)...
March 21, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/28320727/primary-clofazimine-and-bedaquiline-resistance-among-isolates-from-patients-with-multidrug-resistant-tuberculosis
#17
Jian Xu, Bin Wang, Minghao Hu, Fengmin Huo, Shaochen Guo, Wei Jing, Eric Nuermberger, Yu Lu
Clofazimine has been repurposed for the treatment of tuberculosis especially for MDR-TB. To test the susceptibility to clofazimine for Mycobacterium tuberculosis clinical isolates, MICs of clofazimine were determined using the microplate Alamar blue assay (MABA) method for 80 drug-resistant isolates and 10 drug-susceptible isolates for comparison. Five clofazimine-resistant strains isolated from previously treated pre-XDR and XDR-TB patients without prior exposure to clofazimine or bedaquiline had clofazimine MICs ≥1...
March 20, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28320336/multidrug-resistant-tuberculosis-in-ethiopian-settings-and-its-association-with-previous-history-of-anti-tuberculosis-treatment-a-systematic-review-and-meta-analysis
#18
Setegn Eshetie, Mucheye Gizachew, Mulat Dagnew, Gemechu Kumera, Haile Woldie, Fekadu Ambaw, Belay Tessema, Feleke Moges
BACKGROUND: Efforts to control the global burden of tuberculosis (TB) have been jeopardized by the rapid evolution of multi-drug resistant Mycobacterium tuberculosis (MTB), which is resistant to at least isoniazid and rifampicin. Previous studies have documented variable prevalences of multidrug-resistant tuberculosis (MDR-TB) and its risk factors in Ethiopia. Therefore, this meta-analysis is aimed, firstly, to determine the pooled prevalence of MDR-TB among newly diagnosed and previously treated TB cases, and secondly, to measure the association between MDR-TB and a history of previous anti-TB drugs treatment...
March 20, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28304162/rational-design-synthesis-and-biological-evaluation-of-heterocyclic-quinolones-targeting-the-respiratory-chain-of-mycobacterium-tuberculosis
#19
Weiqian David Hong, Peter D Gibbons, Suet C Leung, Richard Amewu, Paul A Stocks, Andrew Valentine Stachulski, Pedro C Horta, Maria Lurdes Santos Cristiano, Alison E Shone, Darren Moss, Alison Ardrey, Raman Sharma, Ashley J Warman, Paul T P Bedingfield, Nicholas E Fisher, Ghaith Aljayyoussi, Sally Mead, Maxine Caws, Neil G Berry, Stephen A Ward, Giancarlo A Biagini, Paul M O'Neill, Gemma Louise Nixon
A High-throughput screen (HTS) was undertaken against the respiratory chain dehydrogenase component, NADH:menaquinone oxidoreductase (Ndh) of Mycobacterium tuberculosis (Mtb). 11,000 compounds were selected for the HTS based on the known phenothiazine Ndh inhibitors, trifluoperazine and thioridazine. Combined HTS (11,000 compounds) and in-house screening of a limited number of quinolones (50 compounds) identified ~100 hits and four distinct chemotypes, the most promising of which contained the quinolone core...
March 17, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28284273/outcomes-and-costs-of-out-patient-mdr-tb-care-in-the-usa
#20
Suzanne M Marks, Yael Hirsch-Moverman, Barbara Seaworth, Katya Salcedo, Edward A Graviss, Lori Armstrong, Lisa Armitige, Jennifer Flood, Sundari Mase
No abstract text is available yet for this article.
April 1, 2017: International Journal of Tuberculosis and Lung Disease
keyword
keyword
75565
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"